Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07706673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ESCUDDO Long Term Follow Up

Study acronym: ESCUDDO LTFU
StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 2 changed
Primary endpoint reworded 2 of 2 changed
See other at-risk trials from National Cancer Institute (NCI)

Record History

  1. Primary endpoint(s) modified Interventions: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Recombinant Human Papillomavirus Nonavalent Vaccine… to Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Recombinant Human Papillomavirus Nonavalent Vaccine… · Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 3 of 3 entries Show 3 more changesShow less
    • Interventions: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Recombinant Human Papillomavirus Nonavalent Vaccine… to Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed (Biological), Recombinant Human Papillomavirus Nonavalent Vaccine…
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Primary endpoint(s) modified Phase changed: not specified → Phase 4 · Enrollment increased: 9700 → 13700 participants · Interventions modified · 3 morev7 Show 6 more changesShow less
    • Phase changed: not specified → Phase 4
    • Enrollment increased: 9700 → 13700 participants
    • Interventions modified
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints expanded, about 21 words
    • Study description expanded, about 33 words

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv6
  4. Enrolling by invitation only Trial arms changed: 1 → 3 · Start date changed from estimate of Sep 17, 2026 to Aug 11, 2026 · Site contact updatedv5 Show 3 more changesShow less
    • Trial arms changed: 1 → 3
    • Start date changed from estimate of Sep 17, 2026 to Aug 11, 2026
    • Site contact updated
  5. Start date: Aug 3, 2026 to Sep 17, 2026 Eligibility criteria expanded, about 66 words · Study description expanded, about 49 words · Study title shortened, about 37 words · 1 morev4 Show 4 more changesShow less
    • Eligibility criteria expanded, about 66 words
    • Study description expanded, about 49 words
    • Study title shortened, about 37 words
    • Study arms: 1 to 3

    See this version in full on ClinicalTrials.gov ↗

Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Collaborators expanded, about 5 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
Trial Details
NCT Number NCT07706673
Lead Sponsor National Cancer Institute (NCI)
Collaborators: Merck Sharp and Dohme LLC
Conditions Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
Enrollment 13,700 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov